Sagimet rises after denifanstat succeeds in late stage trial

[Genetic engineering concept. Medical science. Scientific Laboratory.]
metamorworks/iStock via Getty Images

* Sagimet Biosciences (NASDAQ:SGMT [https://seekingalpha.com/symbol/SGMT]) announced positive results from a late-stage trial of denifanstat, a treatment for moderate to severe acne vulgaris, which was conducted by its partner, Ascletis Bioscience, in China.
* The trial successfully achieved all primary and secondary objectives.
* At the 12-week mark, patients treated [https://seekingalpha.com/pr/20278762-denifanstat-achieved-all-endpoints-in-the-treatment-of-moderate-to-severe-acne-in-phase-3]with denifanstat experienced treatment success rates that were more than double those of the placebo group, showing significant improvements in both inflammatory and non-inflammatory acne lesions.
* Overall, denifanstat was well tolerated by participants. Following the announcement, SGMT stock rose approximately 6.3%.

MORE ON SAGIMET BIOSCIENCES

* Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts [https://seekingalpha.com/article/4828279-denifanstat-advances-sagimet-builds-momentum-toward-2026-readouts]
* Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4819912-sagimet-biosciences-inc-sgmt-presents-at-cantor-global-healthcare-conference-2025-transcript]
* Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold [https://seekingalpha.com/article/4818121-sagimet-biosciences-strong-denifanstat-pipeline-progress-funding-overhang-hold]
* Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero [https://seekingalpha.com/news/4503050-viking-genfit-sagimet-jump-novo-akero-deal]
* MASH drug developers rise as FDA accepts lenient trial requirement [https://seekingalpha.com/news/4489702-fda-accepts-lenient-mash-trial-requirement]